Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Bullboard Posts
Comment by icecubeon Aug 26, 2015 1:23pm
28 Views
Post# 24053042

RE:RE:RE:RE:HIGHLIGHTS THOMSON REUTERS I/B/E/S MEAN

RE:RE:RE:RE:HIGHLIGHTS THOMSON REUTERS I/B/E/S MEAN
Styless wrote:
truthseeker2012 wrote: So where is a copy of the financing agreement with the bank? Why don't you post it? 


hey moron - it's on SEDAR. Check material reports filed on April 23rd.
It wasn't a bank who lent them the money. Banks aren't stupid. It was a fund. A fund who's chargining 10.25% interest.

You're a real moron Lieseeker.

This is what Cipher said in their last MD&A report:

As of June 30, 2015, the Company was not able to fulfill a financial covenant as stipulated under the Notes which constituted an event of default. Since the Company did not have an unconditional right to defer the settlement of the debt for at least 12 months, IFRS requires the liability to be classified as current as at June 30, 2015. The carrying amount of the debt is $33,864 as of June 30, 2015. On July 31, 2015, the Company received an irrevocable waiver of the covenant violation and as a result the lender cannot demand payment of the Notes as a result of the breach. No terms of the Notes were amended as a result of the waiver. The breach occurred due to the timing of the closing of the Innocutis acquisition on April 13, 2015 which resulted in not having a full quarter of Innocutis' results included in consolidated net revenue for the quarter. The covenant relates to consolidated net revenue for the quarter ended June 30, 2015, which was $9 million and the Company reported actual consolidated net sales of $8.835 million. The Company expects the Notes to be classified as long term under IFRS at September 30, 2015.






You beat me to it. :) As well as being more generous in providing some of the actual information.
Bullboard Posts